Oxamniquine is recognized as second-line treatment for the treatment of schistosomiasis [praziquantel remains the first-line choice for all forms of schistosomiasis]. Noting that there are significant research gaps for medicines for children in this area, the EMLc Subcommittee decided to endorse this product as essential but highlighted the need for adequate studies to determine the effectiveness and safety of it in children.